Results 1 to 10 of about 59,439 (317)

Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review

Journal of Cannabis Research, 2022
Aim We undertook this systematic review to determine the efficacy and safety of cannabis-based medicine as a treatment for behavioral, psychological, and motor symptoms associated with neurocognitive disorders.
Anees Bahji, Natasha Breward, Whitney Duff, Nafisa Absher, Scott B. Patten, Jane Alcorn, Darrell D. Mousseau   +6 more
doaj   +1 more source

Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 survey

BMC Primary Care, 2022
Background Medicinal cannabis (MC) products have been available on prescription in Australia for around six years. General practitioners (GPs) are at the forefront of MC prescribing and recent years have seen substantial increases in prescription numbers.
Zeeta Bawa, Danielle McCartney, Ramesh Manocha, Iain S. McGregor   +3 more
doaj   +1 more source

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)

Harm Reduction Journal, 2022
Background Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical cannabis products.
Nicholas Lintzeris, Llewellyn Mills, Sarah V. Abelev, Anastasia Suraev, Jonathon C. Arnold, Iain S. McGregor   +5 more
doaj   +1 more source

Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression

OncoImmunology, 2023
During solid tumor progression, the tumor microenvironment (TME) evolves into a highly immunosuppressive milieu. Key players in the immunosuppressive environment are regulatory myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor ...
Iris Wyrobnik, Miryam Steinberg, Anat Gelfand, Ronen Rosenblum, Yara Eid Mutlak, Liron Sulimani, Shiri Procaccia, Yishai Ofran, Hila Novak-Kotzer, David Meiri   +9 more
doaj   +1 more source

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Clinical and Translational Science, 2023
Global interest in the non‐intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity of health conditions.
Jonathon C. Arnold, Danielle McCartney, Anastasia Suraev, Iain S. McGregor   +3 more
doaj   +1 more source

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)

Harm Reduction Journal, 2020
Background In 2016, the Australian federal government passed legislation enabling a range of cannabis-based products to be prescribed to patients by registered healthcare professionals.
Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, Maria Bravo, Thomas Arkell, Jonathon C. Arnold, Melissa J. Benson, Iain S. McGregor   +7 more
doaj   +1 more source

Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey

Journal of Cannabis Research, 2023
Road safety is an important concern amidst expanding worldwide access to legal cannabis. The present study reports on the driving-related subsection of the Cannabis as Medicine Survey 2020 (CAMS-20) which surveyed driving-related behaviors, attitudes ...
Thomas R. Arkell, Sarah V. Abelev, Llewellyn Mills, Anastasia Suraev, Jonathon C. Arnold, Nicholas Lintzeris, Iain S. McGregor   +6 more
doaj   +1 more source

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study

BMC Pediatrics, 2018
Background Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies.
Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant, Richard J. Huntsman   +14 more
doaj   +1 more source

Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11

Frontiers in Psychiatry, 2022
IntroductionSynthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others,
Richard C. Kevin, Richard C. Kevin, Elizabeth A. Cairns, Elizabeth A. Cairns, Rochelle Boyd, Rochelle Boyd, Jonathon C. Arnold, Jonathon C. Arnold, Michael T. Bowen, Michael T. Bowen, Iain S. McGregor, Iain S. McGregor, Samuel D. Banister, Samuel D. Banister   +13 more
doaj   +1 more source

A Fenchone Derivative Effectively Abrogates Joint Damage Following Post-Traumatic Osteoarthritis in Lewis Rats

Cells, 2022
Background: In a previous report, we have identified the cannabinoid receptor 2 (CB2) agonist HU308 to possess a beneficial effect in preventing age and trauma-induced osteoarthritis (OA) in mice. The effects of HU308 were largely related to the capacity
Idan Carmon, Reem Smoum, Eli Farhat, Eli Reich, Leonid Kandel, Zhannah Yekhtin, Ruth Gallily, Raphael Mechoulam, Mona Dvir-Ginzberg   +8 more
doaj   +1 more source